Medical care for mixed connective-tissue disease (MCTD) must be individualized and based on the severity and type of organ involvement. Plasmapheresis may be a successful treatment because of the removal of immune complexes in serum and improvement of visceral circulation. 
Because of different presenting symptoms associated with mixed connective-tissue disease (MCTD), consultation with the following specialists should be considered:
A dermatologist should evaluate the skin lesions.
An internal medicine specialist should evaluate organ involvement.
Mixed connective-tissue disease (MCTD) patients have restricted mobility if joint and muscle pain is significant.
Approximately 10% of patients with mixed connective-tissue disease (MCTD) have an increased risk of cancer development during the course of disease. Many affected patients receive immunosuppressive therapy, which may put them at increased risk of nontuberculous mycobacterial and other infections. [34, 35]
Deterrence and prevention of mixed connective-tissue disease (MCTD) includes photoprotection.
What would you like to print?